Baicalein-Driven Activation of the Hypothetical REME1 Gene: A immunoinformatic Approach to Mitigate and Treat Ageing and Pancreatic Cancer

Abstract

 Ageing and age-related diseases, including pancreatic cancer, are intricately linked to molecular
disruptions that compromise cellular integrity and homeostasis. The REME1 gene, a novel
hypothetical anti-ageing gene, is believed to be critical in mitigating these age-related processes.
Mutations in REME1 critical binding pockets reduce expression, resulting in increased redox
stress, telomere shortening, and impaired cellular repair mechanisms hallmarks of ageing that
contribute to the onset of age-related diseases, particularly pancreatic cancer. This research
explores the potential of Baicalein, a natural compound, as a therapeutic ligand to restore REME1
expression. In silicon docking studies show that Baicalein binds effectively to the mutated REME1
binding pockets, stabilizing its structure, and enhancing gene expression. This work seeks to
assess the probability of Baicalein, which is a flavonoid obtained from natural products, acting as
a therapeutic ligand for the replacement of REME1. Baicalein shows promising binding
characteristics with REME1 binding domains which were PDB-transformed sites thus implying
good affinity. In alleviating these alterations, REME1 is fully restored and therefore possesses its
three essential functions; compromising oxidative stress, maintaining the integrity of the
telomeres, and aiding cellular repair mechanisms which in elevated levels may offer treatment for
old age and other related disorders such as Pancreatic cancer. Upregulation of REME1 is further
supported through key molecular pathways, including AMPK, Akt, NF-κB, TGF-β, LXRα,
SREBP1, and the Warburg effect. It is observed that these pathways uniformly reduce oxidative
stress, and NEFA metabolism, and enhance cellular operation. More importantly, when
inflammation is modulated and mitochondria bioenergetics are altered, a most favourable outcome
for energy intake and utilization appears by the upregulation of REME1. Thus, this upregulation
targets ageing and age-related diseases including pancreatic cancer. In general, this type of
research underscores the utility of REME1 in cancer and ageing therapies and its importance
resulting from novel cancer strategies which are computational and thus grant grounds for possible
further laboratory exploration.